1. Home
  2. TECX vs TWN Comparison

TECX vs TWN Comparison

Compare TECX & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$29.47

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

TWN

Taiwan Fund Inc. (The)

HOLD

Current Price

$64.67

Market Cap

351.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
TWN
Founded
2019
N/A
Country
United States
United States
Employees
51
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
393.0M
351.0M
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
TECX
TWN
Price
$29.47
$64.67
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$80.40
N/A
AVG Volume (30 Days)
323.2K
36.0K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$26.45
52 Week High
$35.99
$67.83

Technical Indicators

Market Signals
Indicator
TECX
TWN
Relative Strength Index (RSI) 54.30 53.84
Support Level $16.83 $59.82
Resistance Level $35.99 $64.25
Average True Range (ATR) 2.85 2.03
MACD -0.27 0.09
Stochastic Oscillator 55.28 43.82

Price Performance

Historical Comparison
TECX
TWN

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About TWN Taiwan Fund Inc. (The)

Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.

Share on Social Networks: